{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:44:39Z","timestamp":1792806279038,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.diabres.2026.113493","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:41:22Z","timestamp":1786376482000},"page":"113493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP\/GLP-1 receptor agonist in adults with type 2 diabetes"],"prefix":"10.1016","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2100-5076","authenticated-orcid":false,"given":"Artur","family":"Dziewierz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9321-1693","authenticated-orcid":false,"given":"Natalia","family":"Kulicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1617-8426","authenticated-orcid":false,"given":"Krzysztof","family":"\u0141upina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0312-4517","authenticated-orcid":false,"given":"Natalia","family":"Maruszak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1749-0811","authenticated-orcid":false,"given":"Aleksandra","family":"Ga\u0142uszka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Domienik-Kar\u0142owicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rulkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew","family":"Siudak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113493_b0005","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes-2025. Diabetes Care 2025;48(1 Suppl 1):S181-S206. https:\/\/doi.org\/10.2337\/dc25-S009.","DOI":"10.2337\/dc25-S009"},{"key":"10.1016\/j.diabres.2026.113493_b0010","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.2147\/DDDT.S559919","article-title":"The clinical application of GLP-1RAs and GLP-1\/GIP dual receptor agonists based on pharmacological mechanisms: a review","volume":"19","author":"Liu","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.diabres.2026.113493_b0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-025-01623-w","article-title":"GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation","volume":"17","author":"Movahednasab","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.diabres.2026.113493_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions","volume":"86","author":"Moiz","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.diabres.2026.113493_b0025","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001453","article-title":"2026 AHA\/ACC\/ADA\/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines","author":"Ndumele","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2026.113493_b0030","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1111\/dom.70548","article-title":"Real-world treatment trajectories preceding GLP-1 receptor agonist initiation in type 2 diabetes: a descriptive UK population-based cohort study on adherence to national clinical guidelines","volume":"28","author":"Ulrich","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113493_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108686","article-title":"Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care","volume":"173","author":"Bonora","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2026.113493_b0040","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/ajhp\/zxac046","article-title":"Real-world evaluation of insulin requirements after GLP1 agonist or SGLT2 inhibitor initiation and titration","volume":"79","author":"George","year":"2022","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.diabres.2026.113493_b0045","first-page":"52","article-title":"Reducing or discontinuing insulin or sulfonylurea when initiating a glucagon-like peptide-1 agonist","volume":"41","author":"Herron","year":"2024","journal-title":"Fed Pract"},{"key":"10.1016\/j.diabres.2026.113493_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2026.103991","article-title":"Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making","volume":"96","author":"Moiz","year":"2026","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.diabres.2026.113493_b0055","doi-asserted-by":"crossref","first-page":"250","DOI":"10.33963\/v.phj.107918","article-title":"Underutilization of GLP-1 receptor agonists for non-diabetic weight management by cardiologists in Poland","volume":"84","author":"Dziewierz","year":"2026","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.diabres.2026.113493_b0060","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1111\/dom.16590","article-title":"Low long-term persistence with GLP-1 receptor agonists treatment: real-world evidence from a large polish cohort","volume":"27","author":"Siudak","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113493_b0065","doi-asserted-by":"crossref","unstructured":"Salvatore M, Zhang B, Tang H, Lu Y, Zhang D, Zhou T, et al. Real-world comparative outcomes of GLP-1 RA and semaglutide prescription among individuals with type 2 diabetes. medRxiv 2025:2025.06.03.25328908. https:\/\/doi.org\/10.1101\/2025.06.03.25328908.","DOI":"10.1101\/2025.06.03.25328908"},{"key":"10.1016\/j.diabres.2026.113493_b0070","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3390\/nu18111761","article-title":"Adherence and persistence with GLP-1-based therapies: international real-world evidence and the role of nutritional and lifestyle support \u2014 a narrative review","volume":"18","author":"Dziewierz","year":"2026","journal-title":"Nutrients"},{"key":"10.1016\/j.diabres.2026.113493_b0075","first-page":"1636","article-title":"Persistently low initiation of GLP-1 receptor agonists for weight management in individuals without diabetes in Poland: a major unmet need","volume":"21","author":"Dziewierz","year":"2025","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.diabres.2026.113493_b0080","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023489","article-title":"Switching to versus addition of incretin-based drugs among patients with type 2 diabetes taking sodium-glucose cotransporter-2 inhibitors","volume":"11","author":"Lau","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.diabres.2026.113493_b0085","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1900\/RDS.2011.8.323","article-title":"The role of incretin therapy at different stages of diabetes","volume":"8","author":"Cernea","year":"2011","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.diabres.2026.113493_b0090","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12933-025-02737-1","article-title":"Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes","volume":"24","author":"Chaiyakunapruk","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2026.113493_b0095","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","volume":"385","author":"Simms-Williams","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2026.113493_b0100","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.3390\/biomedicines13081924","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists in cardiovascular-kidney-metabolic syndrome","volume":"13","author":"Gajjar","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.diabres.2026.113493_b0105","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.18549\/PharmPract.2019.4.1588","article-title":"Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series","volume":"17","author":"Lajthia","year":"2019","journal-title":"Pharm Pract (Granada)"},{"key":"10.1016\/j.diabres.2026.113493_b0110","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/dom.12802","article-title":"Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: a randomized controlled trial in patients with type 2 diabetes","volume":"19","author":"Nauck","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113493_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1438318","article-title":"Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis","volume":"16","author":"Karimi","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabres.2026.113493_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1032793","article-title":"Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: a real-world data study","volume":"13","author":"Kim","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabres.2026.113493_b0125","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4093\/dmj.2025.0242","article-title":"Exploring the side effects of GLP-1 receptor agonist: to ensure its optimal positioning","volume":"49","author":"Kim","year":"2025","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.diabres.2026.113493_b0130","doi-asserted-by":"crossref","first-page":"242","DOI":"10.26502\/acmcr.96550740","article-title":"A critical analysis of the clinical use of incretin-based therapies: efficacy and adverse events","volume":"9","author":"Radparvar","year":"2025","journal-title":"Arch Clin Med Case Rep"},{"key":"10.1016\/j.diabres.2026.113493_b0135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11906-026-01374-7","article-title":"Should incretin agonist-based drugs be considered for first-line antihypertensive therapy?","volume":"28","author":"Kylies","year":"2026","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.diabres.2026.113493_b0140","doi-asserted-by":"crossref","DOI":"10.1080\/08037051.2026.2676362","article-title":"Reduced antihypertensive treatment with maintained ambulatory blood pressure control following weight loss in type 2 diabetes","volume":"35","author":"Gladzki","year":"2026","journal-title":"Blood Press"},{"key":"10.1016\/j.diabres.2026.113493_b0145","doi-asserted-by":"crossref","DOI":"10.1080\/08037051.2026.2688620","article-title":"Weight loss and antihypertensive de-escalation in type 2 diabetes: accounting for concurrent withdrawal of cardiometabolic agents","volume":"35","author":"Biswas","year":"2026","journal-title":"Blood Press"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726004134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726004134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:13:18Z","timestamp":1792804398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726004134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"alternative-id":["S0168822726004134"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113493","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP\/GLP-1 receptor agonist in adults with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113493","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113493"}}